G.H. Raisoni Department of Microbiology and Biotechnology

Study Explains Molecular Basis of Long COVID Symptoms

Retrieved on: 
Tuesday, June 7, 2022
NYU Langone Health, Human, Macrophage, Infection, Biology, COVID, Cognition, Research, Cell, Brain, Anxiety, Lung, Influenza A virus, Behavior, Doctor of Philosophy, Pathology, Depression, Olfactory bulb, RNA, Degenerative disease, New York University Grossman School of Medicine, Inflammation, Mortimer, Weill Cornell Medicine, Smell, National Institutes of Health, Harvard University, Biophysics, Science Translational Medicine, Cell biology, Patient, Influenza, Systems biology, Medical laboratory, Scar, National, COVID-19, Immune system, Mouse, Columbia University, Severe acute respiratory syndrome coronavirus 2, NYU, Cytokine, G.H. Raisoni Department of Microbiology and Biotechnology, Mark (given name), Virus, Microglia, Department, SARS-COV-2, Tissue, Bacteria, Nasal cavity, Radical behaviorism, Vaccine, Medicine, Microbiology

NEW YORK, June 7, 2022 /PRNewswire/ --A new study provides a better understanding of how the pandemic virus causes depression, anxiety, and the loss of concentration known as "brain fog" in patients that develop long COVID.

Key Points: 
  • NEW YORK, June 7, 2022 /PRNewswire/ --A new study provides a better understanding of how the pandemic virus causes depression, anxiety, and the loss of concentration known as "brain fog" in patients that develop long COVID.
  • Published online June 7in Science Translational Medicine, the study is the first to show that hamsters previously infected with SARS-CoV-2 develop a unique inflammatory response in olfactory tissue, say the study authors.
  • The findings also confirmed that the prolonged immune reactions seen in long COVID are happening in tissues where the SARS-COV-2 virus is no longer present.
  • Depression and anxiety are common attributes of long COVID, and these behavioral abnormalities were found to correlate with unique changes to the brain cell biology, the researchers say.

Mechanism Revealed Behind Loss of Smell with COVID-19

Retrieved on: 
Wednesday, February 2, 2022
Infection, DNA, Human body, NYU Langone Health, Patient, Immune system, Cell, Brain, University, OR, Chromosome, Mortimer, Icahn School of Medicine at Mount Sinai, Howard Hughes Medical Institute, Neuron, Microglia, Emotion, Headache, Human, Columbia University, Anosmia, Cognition, Genetics, Cytokine, Gene expression, Inflammation, Anatomy, COVID, Nasal cavity, COVID-19, National, Mammal, Smell, Nose, G.H. Raisoni Department of Microbiology and Biotechnology, Gene, Steroid, New York University Grossman School of Medicine, Chromatin, University of California, Davis, Reading, School, Doctor of Philosophy, Depression, Stavros, Medical school, NYU, Department, Cell biology, Severe acute respiratory syndrome coronavirus 2, Protein, National Institutes of Health, Hyposmia, Davis, MT, Aroma compound, Pharmaceutical industry, Vaccine, Microbiology

One unique symptom of COVID-19 infection is loss of smell without the stuffy nose seen with other infections like the common cold, researchers say.

Key Points: 
  • One unique symptom of COVID-19 infection is loss of smell without the stuffy nose seen with other infections like the common cold, researchers say.
  • In most cases, the smell loss lasts only a few weeks, but for more than 12 percent of COVID-19 patients, olfactory dysfunction persists in the form of ongoing reduction in the ability to smell (hyposmia) or changes in how a person perceives the same smell (parosmia).
  • To gain insight into COVID-19-induced smell loss, the current authors explored the molecular consequences of SARS-CoV-2 infection in golden hamsters and in olfactory tissue taken from 23 human autopsies.
  • Experiments in hamsters recorded over time revealed that downregulation of olfactory neuron receptors persisted after short-term changes that might affect the sense of smell had naturally recovered.

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

Retrieved on: 
Tuesday, January 11, 2022
Lung, Patient, Pneumonia, Mount Sinai, Life Science Alliance, MSE, European Molecular Biology Organization, Clinical trial, COVID-19, Icahn School of Medicine at Mount Sinai, Severe acute respiratory syndrome coronavirus 2, Safety, Therapeutic index, PHM, National university, Disease, Department, EMBO, Animal, Rockefeller University, Cold, Viral load, Company, Internal medicine, G.H. Raisoni Department of Microbiology and Biotechnology, European, Hospital, Phase, Hospital das Clínicas, Cold Spring Harbor Laboratory, PharmaMar, Delta, Pulse oximetry, Coronavirus, Omicron, Pharmaceutical industry, Microbiology

MADRID, Jan. 11, 2022 /PRNewswire/ -- PharmaMar (MSE:PHM) has announced today the publication of an article in the Life Science Alliance journal, entitled "Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19"[1] which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant.

Key Points: 
  • - PharmaMar confirms in vitroactivity of plitidepsin against several variants, including Delta and Omicron.
  • - The Life Science Alliance journal is co-founded by the Rockefeller University, the European Molecular Biology Organization (EMBO) and Cold Spring Harbor Laboratory.
  • The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission.
  • Jos Mara Fernndez Sousa-Faro, Ph.D., PharmaMar's Chairman stated "all the data we have seen so far with plitidepsin corroborate our initial hypothesis about its antiviral activity.

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

Retrieved on: 
Tuesday, January 11, 2022
Lung, Patient, Pneumonia, Mount Sinai, Life Science Alliance, MSE, Clinical trial, COVID-19, Icahn School of Medicine at Mount Sinai, Severe acute respiratory syndrome coronavirus 2, Therapeutic index, Safety, PHM, Disease, Department, Animal, Viral load, Internal medicine, G.H. Raisoni Department of Microbiology and Biotechnology, Phase, Hospital, Hospital das Clínicas, PharmaMar, Delta, Pulse oximetry, Coronavirus, Omicron, Pharmaceutical industry, Microbiology

According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index.

Key Points: 
  • According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index.
  • Laboratory in vivo studies have also demonstrated a preferential distribution of plitidepsin to lung tissue, which is the organ primarily affected in patients with COVID-19.
  • The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission.
  • Jos Mara Fernndez Sousa-Faro, Ph.D., PharmaMar's Chairman stated "all the data we have seen so far with plitidepsin corroborate our initial hypothesis about its antiviral activity.

Susan Tousi Joins Vizgen as Scientific Advisor

Retrieved on: 
Tuesday, November 30, 2021
Science, Health, Oncology, Research, Harvard University, Journal of Cellular and Molecular Medicine, Genomics, CEO, National academy, Central Waqf Council, Cell, Neuroscience, Technology, Disease, Industry, Wyss Institute, Bionics, Health, SAB, Kodak, Engineering, Developmental biology, G.H. Raisoni Department of Microbiology and Biotechnology, Running, Department, COVID-19, Invention, Hewlett-Packard, Howard Hughes Medical Institute, Wyss Institute for Biologically Inspired Engineering, Twitter, Research, Fortune, Diversity, Social media, Efficiency, Hospital, Bioinspiration, Data visualization, Drug discovery, Assistant, LinkedIn, Molecular medicine, Infection, Harvard Medical School, Growth, National Academy of Engineering, Management, Medical imaging, MERSCOPE, Vizgen, MERSCOPE, VIZGEN

In addition to Vizgens current scientific consultants, Susan Tousi, Chief Commercial Officer at Illumina, will join the SAB.

Key Points: 
  • In addition to Vizgens current scientific consultants, Susan Tousi, Chief Commercial Officer at Illumina, will join the SAB.
  • The Vizgen Scientific and Technical Advisory Board brings together a group of world-class leaders in life sciences technology to address the growing demand for single-cell spatial genomics research, said Terry Lo, President and CEO of Vizgen.
  • Susan Tousi brings to Vizgens SAB more than 25 years of R&D and business leadership experience at Fortune 100 technology companies, most recently in the life sciences industry.
  • Currently at Illumina , Susan oversees global sales, commercial operations, and commercial strategy and enablement.

Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis

Retrieved on: 
Wednesday, October 20, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GSK, DOD, Literature, IND, Clinical trial, Immune system, Defense Health Agency, CDC, U.S. Department of Defense Strategy for Operating in Cyberspace, JPM, Joint Program Executive Office Chemical and Biological Defense, Private Securities Litigation Reform Act, COVID-19, Professor, Antibody, Doctor of Philosophy, Perelman School of Medicine at the University of Pennsylvania, Goal, Annual report, Severe acute respiratory syndrome coronavirus 2, Infection, Disease, Department, Research, U.S. Securities and Exchange Commission, Nasdaq, Viral load, Safety, CEO, Human, SARS-COV-2, Biotechnology, Patient, University, Epitope, Forward-looking statement, Penn Center, SEC, DHA, Manuscript, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, G.H. Raisoni Department of Microbiology and Biotechnology, Therapy, Vaccine, Pharmaceutical industry

IMM-BCP-01 contains three monoclonal, antibodies that bind to non-overlapping regions of the spike protein, including highly conserved epitopes.

Key Points: 
  • IMM-BCP-01 contains three monoclonal, antibodies that bind to non-overlapping regions of the spike protein, including highly conserved epitopes.
  • The three antibodies, derived from human immune response, bind to the spike protein in a non-competitive manner.
  • The second antibody is also directed at a broadly conserved epitope and exhibits an avidity-based binding mechanism.
  • The third antibody binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop.

Off-Target Immune System Response Could Predict COVID-19 Severity

Retrieved on: 
Thursday, September 9, 2021

Patients with these elevated levels of autoimmune antibodies were five to seven times more likely to develop severe disease than those whose antibodies levels were stable.

Key Points: 
  • Patients with these elevated levels of autoimmune antibodies were five to seven times more likely to develop severe disease than those whose antibodies levels were stable.
  • Publishing in the journal Life Science Alliance online Sept. 9, the team's latest work is based on the nature of antibodies, they explain, immune proteins that target invading bacteria and viruses.
  • Levels of anti-DNA and anti- phosphatidylserine antibodies were then strongly linked to severity of illness.
  • "Our study adds evidence to the underlying premise of the disease that the misguided immune system's response is doing more damage than the actual viral infection itself."

Labroots Announces 7th Annual Microbiology Virtual Week Online Event Breaking Barriers to Sharing Scientific Research, scheduled September 7-9, 2021

Retrieved on: 
Thursday, September 2, 2021
Research, Learning, HIV, COVID-19, MD, G.H. Raisoni Department of Microbiology and Biotechnology, Interact, Importance, Survival, Biophysical environment, Associate professor, Virulent Newcastle disease, Disease, Degenerative disease, RNA interference, RNA, Institute, Science, Gordon and Betty Moore Foundation, UTMB, Social media, Mount Sinai, Viroid, University, Department, Mount, Battle, Infection, Severe acute respiratory syndrome coronavirus 2, News, DNA replication, Social, Division, Diagnosis, Program, University of California, Riverside, Susceptibility, Pathology, Icahn School of Medicine at Mount Sinai, Labroots, Continuing education, Orthornavirae, PCR, Doctor of Philosophy, Human, Industry, Flow cytometry, Fellow, Host, Entertainment, Pharmaceutical industry, Vaccine, Management, Online shopping

The comprehensive 3-day agenda will include over 30 presentations from academia and industry prominent speakers , including a handful of stellar keynote deliveries.

Key Points: 
  • The comprehensive 3-day agenda will include over 30 presentations from academia and industry prominent speakers , including a handful of stellar keynote deliveries.
  • Join the online conversation and use the official event hashtag #LRmicro to stay up to date on the latest information.
  • Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more.
  • Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities.